FDA grants priority review for Intellia rare genetic disease therapy
Intellia Therapeutics’ experimental gene-editing treatment for a rare genetic disease has received U.S. FDA priority review status, putting the stock back in focus among investors.
Intellia Therapeutics (NTLA) drew investor attention on Tuesday after the U.S. Food and Drug Administration granted priority review to its experimental gene-editing treatment for a rare genetic disease. The development comes just days after Cathie Wood’s ARK Invest increased its stake in the company.